Keane's Corner VL

Focus on ASCO GU 2016

Details
Thomas E. Keane, MBBCh, FRCSI, FACS, is Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston. Dr. Keane specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served as principal investigator or coinvestigator on more than 20 major clinical and preclinical studies, funded by grants from the National I...

2016 ASCO GU: Renal Cancer Review

Details
Thomas E. Keane, MBBCh, FRCSI, FACS, is Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston. Dr. Keane specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served as principal investigator or coinvestigator on more than 20 major clinical and preclinical studies, funded by grants from the National I...

2016 ASCO GU: Prostate Cancer Conference Highlights

Details
Thomas E. Keane, MBBCh, FRCSI, FACS, is Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston. Dr. Keane specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served as principal investigator or coinvestigator on more than 20 major clinical and preclinical studies, funded by grants from the National I...

2015 Uro-Oncology Highlights - "What we have learned in the past year"

Details
Thomas Keane discusses advancements in clinical treatment for Prostate Cancer - Bladder Cancer and Renal Cancer over 2015

Impact of the CCP Test on Physician and Patient Treatment Selection

Details
Impact of the CCP Test on Physician and Patient Treatment Selection Review of the abstract: The CCP test is a validated molecular assay that assesses prostate cancer-specific disease progression and mortality risk when combined with clinicopathologic parameters. The results from PROCEDE-1000, a large, prospective registry designed to evaluate the impact of the CCP test regarding shared treatment d...

Perspectives - Releasing the Brakes on Cancer Immunotherapy

Details
Perspectives - Releasing the Brakes on Cancer Immunotherapy commentary from a NEJM Perspectives Thomas E. Keane, MBBCh, FRCSI, FACS, is Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston. Dr. Keane specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served as principal investigator or coinvestiga...

The Dose-Dependent Effect Of ADT For Localized Prostate Cancer On Adverse Cardiac Events

Details
The Dose-Dependent Effect Of Androgen Deprivation Therapy For Localized Prostate Cancer On Adverse Cardiac Events - Highlights of a recent publication Article Title: THE DOSE-DEPENDENT EFFECT OF ANDROGEN DEPRIVATION THERAPY FOR LOCALIZED PROSTATE CANCER ON ADVERSE CARDIAC EVENTS ABSTRACT Objectives: To investigate the dose-dependent effect of androgen deprivation therapy (ADT) on adverse cardiac e...

ASCO 2015 - Docetaxel and/or Zoledronic Acid for Hormone-naïve Prostate Cancer

Details
ASCO 2015 - Docetaxel and/or Zoledronic Acid for Hormone-naïve Prostate Cancer: First Overall Survival Results from STAMPEDE Thomas E. Keane, MBBCh, FRCSI, FACS Professor and Chairman of the Department of Urology Medical University of South Carolina, Charleston, SC USA SEE RELATED CONTENT Click HERE to read the session highlights from ASCO 2015 BIOGRAPHY Thomas E. Keane, MBBCh, FRCSI, FACS special...

ASCO 2015 - Prostate & Bladder Cancers

Details
ASCO 2015 - Prostate & Bladder Cancers Tom Keane, MBBCh, FRCSI, FACS discusses the following abstracts from ASCO 2015: Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients with metastatic castration-resistant prostate cancer and poor prognosis First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cance...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe